Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Gyre Therapeutics's Enterprise Value is $694.8 Mil.
Gyre Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.9 Mil. Therefore, Gyre Therapeutics's EV-to-OCF for today is -140.79.
The historical rank and industry rank for Gyre Therapeutics's EV-to-OCF or its related term are showing as below:
GYRE'
s EV-to-OCF Range Over the Past 10 Years
Min: -289.81 Med: 82.55 Max: 839.81
Current: -140.79
During the past 5 years, the highest EV-to-OCF of Gyre Therapeutics was 839.81. The lowest was -289.81. And the median was 82.55.
GYRE's EV-to-OCF is ranked better than 96.94% of 1407
companies
in the Biotechnology industry
Industry Median: -3.61
vs GYRE: -140.79
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gyre Therapeutics's PE Ratio (TTM) for today is calculated as:
Gyre Therapeutics's share price for today is $6.90.
Gyre Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gyre Therapeutics EV-to-OCF Related Terms
Gyre Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's EV-to-OCF falls into.
Gyre Therapeutics's current Enterprise Value is $694.8 Mil.
Gyre Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a EV-to-OCF of -140.79 as of Aug. 22, 2026. According to the industry distribution chart, Gyre Therapeutics ranks #43 out of 1407 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Gyre Therapeutics' EV-to-OCF too high?
Gyre Therapeutics' current EV-to-OCF is -140.79. Based on the distribution chart, Gyre Therapeutics ranks #43 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' EV-to-OCF compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #43 out of 1407 companies for EV-to-OCF. This places Gyre Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Gyre Therapeutics's current EV-to-OCF is -140.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.43, compared to a current price of $6.90 — trading 26.8% below its estimated fair value. The current EV-to-OCF is -140.79. Gyre Therapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current EV-to-OCF is -140.79 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.90 is trading 26.8% below its estimated GF Value™ of $9.43.
GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.
Key valuation signals for GYRE:
EV-to-OCF: -140.79
GF Value™: $9.43 vs. price of $6.90 (26.8% below fair value)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
